Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Comic: Stimulus Hopes, Vaccine Optimism To Drive Sentiment In The Week Ahead

Published 12/19/2020, 07:49 AM
Updated 12/19/2020, 07:54 AM

By Jesse Cohen

Investing.com - Stocks fell on Friday, but Wall Street’s major averages still managed to score weekly gains amid renewed hopes for another fiscal stimulus package and ongoing optimism over Covid-19 vaccine progress.

The Dow Jones Industrial Average declined 124 points, or 0.4%, to end the day at 30,179, while the S&P 500 shed 0.4% to close at 3,709.

Meanwhile, the tech-heavy Nasdaq Composite lost 0.1% to 12,755 and the small-cap Russell 2000 dipped 0.3% to finish the session at 1,972.

All four indexes closed at records in the previous session.

The major averages posted gains for the week, despite Friday’s weakness. The Dow rose 0.4%, while the S&P 500 tacked on 1.3%. The Nasdaq and the Russell outperformed, with both notching a gain of 3.1% over that time frame.

Investors should expect more volatility in the holiday-shortened Christmas week ahead as they monitor fresh developments on the stimulus and vaccine front.

Democratic and Republican lawmakers in Washington were working through the weekend to complete a $900 billion coronavirus aid bill for American individuals and businesses struggling from the economic fallout of pandemic lockdowns.

Both sides say they are close to a deal, but significant differences remain.

Congressional leaders expect to attach the package to a $1.4 trillion spending bill that would fund U.S. government activity through September 2021. Government funding was due to expire on Friday, but lawmakers approved a two-day stopgap bill to buy more time which President Donald Trump signed into law late on Friday.

Congress now faces a Sunday midnight deadline to approve more funding.

Meanwhile, Moderna (NASDAQ:MRNA)'s coronavirus vaccine on Friday became the second to receive emergency use authorization (EUA) from the U.S. Food and Drug Administration.

Millions of doses of the Moderna vaccine are expected to be added to the U.S. rollout, which began last week with healthcare workers.

The FDA announced the authorization a week after the agency authorized a vaccine from Pfizer (NYSE:PFE) and German partner BioNTech (NASDAQ:BNTX).

Latest comments

this afternoon only deliberating or announcing the release of the krakon ?
what?
better enjoy the good times for now. once the badness comes it will be here for a long time....business closures, debt from eviction moratorium and mortgage forbearance, Biden business tax increases.
less volume but the action will play off of news.
Most likely, next week will be quiet. Sideways market continues. In past, some folks sold for tax losses before eoy. However, it is difficult to find folks with losses this year.
anyone taking a vaccine rushed through in less than 8 months and backed by darpa and Bill gates, is a ******* Darwin natural selection at work
Do your job congress i need my calls tp pay out on fed x
I was over confident in their ability and had calls expiring Friday. Good luck to you.
Lets see week ahead
smh
smh
Wish with all these roll outs my BNTX and MRNA stock would start making money instead of going down all the time when everything looks good !!!!
yay! a whole $600 and a provision to end Fed spending at the end of the year should sure send this to all new highs, right?!?!?!
There is no doubt🙂SP 3820-3840, then back to 3600
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.